Nora Sundahl1,2, Alison Tree1,2, Chris Parker3,4. 1. Urological Oncology Department, Royal Marsden Hospital, Downs Road, Sutton, London, SM2 5PT, UK. 2. Radiotherapy and Imaging Division, Institute of Cancer Research, Sutton, London, UK. 3. Urological Oncology Department, Royal Marsden Hospital, Downs Road, Sutton, London, SM2 5PT, UK. chris.parker@icr.ac.uk. 4. Radiotherapy and Imaging Division, Institute of Cancer Research, Sutton, London, UK. chris.parker@icr.ac.uk.
Abstract
PURPOSE OF REVIEW: This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer. RECENT FINDINGS: The phase 3 STAMPEDE trial showed that prostate radiotherapy confers a survival benefit for newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer (HSPC). No survival benefit was noted for those with high volume disease. A subsequent meta-analysis combining the data of the STAMPEDE trial with that of the HORRAD trial corroborated these findings. The phase 2 randomized STOMP trial investigated local treatment of metastases in patients with oligometastatic HSPC, and showed an improvement in hormone therapy-free survival. Local prostate radiotherapy should be offered to patients with newly diagnosed low volume metastatic HSPC. Early clinical evidence suggests that local treatment to metastatic disease might be beneficial for patients with oligometastatic HSPC, but larger trials are awaited.
PURPOSE OF REVIEW: This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer. RECENT FINDINGS: The phase 3 STAMPEDE trial showed that prostate radiotherapy confers a survival benefit for newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer (HSPC). No survival benefit was noted for those with high volume disease. A subsequent meta-analysis combining the data of the STAMPEDE trial with that of the HORRAD trial corroborated these findings. The phase 2 randomized STOMP trial investigated local treatment of metastases in patients with oligometastatic HSPC, and showed an improvement in hormone therapy-free survival. Local prostate radiotherapy should be offered to patients with newly diagnosed low volume metastatic HSPC. Early clinical evidence suggests that local treatment to metastatic disease might be beneficial for patients with oligometastatic HSPC, but larger trials are awaited.
Authors: Liselotte M S Boevé; Maarten C C M Hulshof; André N Vis; Aeilko H Zwinderman; Jos W R Twisk; Wim P J Witjes; Karl P J Delaere; R Jeroen A van Moorselaar; Paul C M S Verhagen; George van Andel Journal: Eur Urol Date: 2018-09-25 Impact factor: 20.096
Authors: Matti Annala; Gillian Vandekerkhove; Daniel Khalaf; Sinja Taavitsainen; Kevin Beja; Evan W Warner; Katherine Sunderland; Christian Kollmannsberger; Bernhard J Eigl; Daygen Finch; Conrad D Oja; Joanna Vergidis; Muhammad Zulfiqar; Arun A Azad; Matti Nykter; Martin E Gleave; Alexander W Wyatt; Kim N Chi Journal: Cancer Discov Date: 2018-01-24 Impact factor: 39.397
Authors: Chad G Rusthoven; Bernard L Jones; Thomas W Flaig; E David Crawford; Matthew Koshy; David J Sher; Usama Mahmood; Ronald C Chen; Brian F Chapin; Brian D Kavanagh; Thomas J Pugh Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal Journal: N Engl J Med Date: 2016-09-14 Impact factor: 91.245
Authors: Piet Ost; Alberto Bossi; Karel Decaestecker; Gert De Meerleer; Gianluca Giannarini; R Jeffrey Karnes; Mack Roach; Alberto Briganti Journal: Eur Urol Date: 2014-09-17 Impact factor: 20.096
Authors: Janine T Erler; Kevin L Bennewith; Thomas R Cox; Georgina Lang; Demelza Bird; Albert Koong; Quynh-Thu Le; Amato J Giaccia Journal: Cancer Cell Date: 2009-01-06 Impact factor: 31.743
Authors: Jelena Belic; Ricarda Graf; Thomas Bauernhofer; Yauheniya Cherkas; Peter Ulz; Julie Waldispuehl-Geigl; Samantha Perakis; Michael Gormley; Jaymala Patel; Weimin Li; Jochen B Geigl; Denis Smirnov; Ellen Heitzer; Mitchell Gross; Michael R Speicher Journal: Int J Cancer Date: 2018-04-10 Impact factor: 7.396
Authors: Sarah Burdett; Liselotte M Boevé; Fiona C Ingleby; David J Fisher; Larysa H Rydzewska; Claire L Vale; George van Andel; Noel W Clarke; Maarten C Hulshof; Nicholas D James; Christopher C Parker; Mahesh K Parmar; Christopher J Sweeney; Matthew R Sydes; Bertrand Tombal; Paul C Verhagen; Jayne F Tierney Journal: Eur Urol Date: 2019-02-28 Impact factor: 20.096